CompletedPhase 2NCT00331006
Rituximab to Treat Severe Hemophilia A
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Carelon Research
- Principal Investigator
- Susan F. Assmann, PhDNERI
- Intervention
- Rituximab(drug)
- Enrollment
- 23 enrolled
- Eligibility
- All sexes
- Timeline
- 2006 – 2012
Study locations (13)
- Children's Hospital of Orange County, Orange, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Tulane University Health Sciences Center, New Orleans, Louisiana, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- UNC at Chapel Hill Hospital, Chapel Hill, North Carolina, United States
- University Hospital of Cleveland, Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00331006 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota